OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor
Francesca Schiano di Cola, Marco Bolchini, Giulia Ceccardi, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 6, pp. 1764-1773
Open Access | Times Cited: 16
Francesca Schiano di Cola, Marco Bolchini, Giulia Ceccardi, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 6, pp. 1764-1773
Open Access | Times Cited: 16
Showing 16 citing articles:
A Scoping Review and Meta-Analysis of Anti-CGRP Monoclonal Antibodies: Predicting Response
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 44
Ja Bin Hong, Kristin Sophie Lange, Lucas Hendrik Overeem, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 7, pp. 934-934
Open Access | Times Cited: 44
Pharmacological differences and switching among anti‐CGRP monoclonal antibodies: A narrative review
Giorgio Dalla Volta, Antonio Munafò, Andrea Burgalassi, et al.
Headache The Journal of Head and Face Pain (2025)
Closed Access | Times Cited: 1
Giorgio Dalla Volta, Antonio Munafò, Andrea Burgalassi, et al.
Headache The Journal of Head and Face Pain (2025)
Closed Access | Times Cited: 1
Ten open questions in migraine prophylaxis with monoclonal antibodies blocking the calcitonin-gene related peptide pathway: a narrative review
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Jean Schoenen, Annelies Van Dycke, Jan Versijpt, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 17
Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers
Mamoru Shibata, Kazuki Fujita, Eri Hoshino, et al.
BMC Neurology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Mamoru Shibata, Kazuki Fujita, Eri Hoshino, et al.
BMC Neurology (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 6
Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Cephalalgia (2023) Vol. 43, Iss. 5, pp. 033310242311776-033310242311776
Open Access | Times Cited: 15
Keisuke Suzuki, Shiho Suzuki, Tomohiko Shiina, et al.
Cephalalgia (2023) Vol. 43, Iss. 5, pp. 033310242311776-033310242311776
Open Access | Times Cited: 15
Calcitonin gene-related peptide-targeted therapy in migraine: current role and future perspectives
Jan Versijpt, Koen Paemeleire, Uwe Reuter, et al.
The Lancet (2025) Vol. 405, Iss. 10483, pp. 1014-1026
Closed Access
Jan Versijpt, Koen Paemeleire, Uwe Reuter, et al.
The Lancet (2025) Vol. 405, Iss. 10483, pp. 1014-1026
Closed Access
Real-world effectiveness and safety of erenumab for the treatment of migraine: A systematic review and meta-analysis
Jaime Fernández-Bravo-Rodrigo, Iván Cavero‐Redondo, Maribel Lucerón‐Lucas‐Torres, et al.
European Journal of Pharmacology (2024) Vol. 976, pp. 176702-176702
Closed Access | Times Cited: 3
Jaime Fernández-Bravo-Rodrigo, Iván Cavero‐Redondo, Maribel Lucerón‐Lucas‐Torres, et al.
European Journal of Pharmacology (2024) Vol. 976, pp. 176702-176702
Closed Access | Times Cited: 3
Persistence, effectiveness, and tolerability of anti‐calcitonin gene–related peptide monoclonal antibodies in patients with chronic migraine
Anna de Dios, Neus Pagès‐Puigdemont, Sergio R. Ojeda, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 65, Iss. 1, pp. 24-34
Closed Access | Times Cited: 3
Anna de Dios, Neus Pagès‐Puigdemont, Sergio R. Ojeda, et al.
Headache The Journal of Head and Face Pain (2024) Vol. 65, Iss. 1, pp. 24-34
Closed Access | Times Cited: 3
What to do with non-responders to CGRP(r) monoclonal antibodies: switch to another or move to gepants?
Marta Waliszewska‐Prosół, Doğa Vurallı, Paolo Martelletti
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Marta Waliszewska‐Prosół, Doğa Vurallı, Paolo Martelletti
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 9
Potential Predictors of Response to CGRP Monoclonal Antibodies in Chronic Migraine: Real-World Data
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García‐Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Carmen Sánchez-Rodríguez, Ana Beatriz Gago‐Veiga, David García‐Azorín, et al.
Current Pain and Headache Reports (2023)
Closed Access | Times Cited: 7
Celia Romero del Rincón, Alicia González‐Martínez, Sonia Quintas, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 4
Open Access | Times Cited: 2
Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti‐calcitonin gene‐related peptide therapies: The PREVENAC study
Ana Beatriz Gago‐Veiga, Noelia Lopez‐Alcaide, Sonia Quintas, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 5
Open Access | Times Cited: 2
Ana Beatriz Gago‐Veiga, Noelia Lopez‐Alcaide, Sonia Quintas, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 5
Open Access | Times Cited: 2
Treatment Outcome After Switching From Galcanezumab to Fremanezumab in Patients With Migraine
Michelle Sojung Youn, Namoh Kim, Mi Ji Lee, et al.
Journal of Clinical Neurology (2024) Vol. 20, Iss. 3, pp. 300-300
Open Access | Times Cited: 2
Michelle Sojung Youn, Namoh Kim, Mi Ji Lee, et al.
Journal of Clinical Neurology (2024) Vol. 20, Iss. 3, pp. 300-300
Open Access | Times Cited: 2
Reducing the Impact of Headache and Allodynia Score in Chronic Migraine: An Exploratory Analysis from the Real-World Effectiveness of Anti-CGRP Monoclonal Antibodies Compared to Onabotulinum Toxin A (RAMO) Study
Danilo Antonio Montisano, Riccardo Giossi, Mattia Canella, et al.
Toxins (2024) Vol. 16, Iss. 4, pp. 178-178
Open Access
Danilo Antonio Montisano, Riccardo Giossi, Mattia Canella, et al.
Toxins (2024) Vol. 16, Iss. 4, pp. 178-178
Open Access
Anti-CGRP and Anti-CGRP Receptor Monoclonal Antibodies for Migraine Prophylaxis: Retrospective Observational Study on 209 Patients
Vittorio Schweiger, Paola Bellamoli, Francesco Taus, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 1130-1130
Open Access
Vittorio Schweiger, Paola Bellamoli, Francesco Taus, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 4, pp. 1130-1130
Open Access
Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal
Yan Tereshko, Simone Dal Bello, Sara Pez, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 23, pp. 7329-7329
Open Access
Yan Tereshko, Simone Dal Bello, Sara Pez, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 23, pp. 7329-7329
Open Access
